Inex Pharmaceuticals Corp.

INEX receives "statement of claim" on gene therapy technology from Protiva Biotherapeutics

Published in Lab Law Weekly, April 28th, 2006

Inex Pharmaceuticals Corp. (IEX) announced that it has received a statement of claim filed by Protiva Biotherapeutics, Inc., in the Supreme Court of British Columbia, regarding its gene therapy technology.

Protiva, a private biotechnology company, was spun-out from INEX in 2001 along with certain intellectual property rights relating to the gene therapy technology.

INEX holds a minority interest in Protiva.

Under its agreements with Protiva, INEX believes it has certain rights to obtain a fully paid-up, exclusive license from Protiva for certain oligonucleotide technology. INEX has been seeking to clarify its rights under these...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Lab Law Weekly

Source: Lab Law Weekly (2006-04-28)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry